Christina Coughlin, MD, PhD - 2022 World Medical Innovation Forum
Christina Coughlin
This speaker appears at this event:

Christina Coughlin, MD, PhD

CEO, CytoImmune

Christina Coughlin, MD, PhD is the Chief Executive Officer of CytoImmune Therapeutics, a clinical stage biotechnology company focused on engineered innate killer cell therapy in oncology. Dr. Coughlin joined CytoImmune from Rubius Therapeutics, Inc. where she served as the Chief Medical Officer and led the clinical development, translational medicine and regulatory efforts in the allogeneic red cell therapy platform. Prior to Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as Chief Medical Officer and was responsible for the development of autologous CAR-T and TCR-T cellular therapies. She also serves as a non-executive director at Avacta Life Sciences, U.K.

Dr. Coughlin has held other leadership roles in the pharmaceutical and biotechnology fields in her career including Chief Medical Officer at Immunocore, heading the development of the soluble TCR platform, and Oncology Asset Team Leader at Pfizer. Dr. Coughlin received her M.D. and Ph.D. from the University of Pennsylvania and completed fellowships in Hematology and Oncology at the Children’s Hospital of Philadelphia and in the Translational Research Group under the direction of Carl June, M.D. at the University of Pennsylvania.